Table 1. The main clinical and biochemical characteristics of the patients received and not received favipiravir.
Values are presented using means ± standard deviations for normally distributed and medians and first and third quartiles in the brackets for the non-normally distributed variables; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: c-reactive protein; WBC: white blood cell; ICU: intensive care unit, SpO2: peripheral capillary oxygen saturation.
| Patients received favipiravir (n: 454) | Patients who not received favipiravir (n: 113) | P-value | |
| Age | 63.0 ± 15.9 | 63.8 ±11.8 | 0.590 |
| Male gender (n %) | 227 (%50) | 68 (%58.8) | 0.053 |
| AST (baseline) U/L | 26 (20-31) | 25 (21-32) | 0.960 |
| ALT (baseline) U/L | 20 (16-26) | 20 (15-30) | 0.650 |
| AST (after 5 days of treatment) U/L | 30 (21-44) | 26 (19-48) | 0.160 |
| ALT (after 5 days of treatment) U/L | 24 (15-40) | 23 (16-45) | 0.800 |
| Albumin (mg/dL) | 35.1 ± 4.6 | 36.8 ± 5.1 | 0.003 |
| CRP (mg/dL) | 72 (26-115) | 33 (14-81) | 0.001 |
| WBC (10³/µl) | 6.6 (4.9-9.1) | 6.5 (5.1-7.8) | 0.300 |
| Lymphocyte (10³/µl) | 1.2 (0.8-1.6) | 1.4 (1-1.8) | 0.001 |
| AST elevation (n %) | 133 (%29.3) | 32 (%28.3) | 0.830 |
| ALT elevation (n %) | 112 (%24.7) | 35 (%29.3) | 0.170 |
| SpO2 (%) | 93(90-94) | 93 (91-94) | 0.167 |
| Respiratory rate (n/minute) | 27(26-30) | 27 (26-29) | 0.681 |
| ICU (n %) | 36 (%7.9) | 9 (%8) | 0.990 |
| Mortality (n %) | 27 (%5.9) | 7 (%6.8) | 0.920 |